Compare Revvity Inc (RVTY) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs DENTSPLY SIRONA Inc — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while DENTSPLY SIRONA Inc trades at $8.83 (market cap $1.73B). The key difference: Revvity Inc is far larger — about 9.8× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| RVTY | XRAY | |
|---|---|---|
Market Cap | $16.98B | $1.73B |
Volume | 1,456,900 | 6,198,582 |
Sector | Health | Health |
52-Week High | $157.36 | $14.68 |
52-Week Low | $82.26 | $8.52 |
Typical Hold Time | 12 Days | 72 Days |
Enterprise Value | $19.30B | $3.80B |
Dividend Yield | 0.18% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
DENTSPLY SIRONA (XRAY) trades at $8.69, down 1.76% on the day and near a 52-week low, reflecting ongoing operational challenges. The stock shows a bearish technical trend with weak moving averages, while fundamentals reveal declining revenue, negative net income margins, and elevated debt levels. Recent Q2 2026 earnings beat expectations but sales fell 4.1%, indicating persistent headwinds in dental markets.
The outlook remains cautious due to margin pressure and competitive threats, though analyst consensus suggests upside to a $13.40 price target. Key risks include execution of the turnaround plan, macroeconomic sensitivity, and high leverage. Investment appeal hinges on successful restructuring and recovery in core dental segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
